The ADSCs with 3–6 passages underwent pre-treatment with visfatin at 50 or 100 ng/mL, which was similar to the medium or high level of breast cancer patients, respectively [23], for 48 h. The gene discussed is NAMPT; the disease is breast carcinoma.